By Fineline Cube Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that SKB565, a dual-payload antibody-drug conjugate (ADC), has received approval from China’s National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of advanced solid tumors. The investigational therapy was developed using the proprietary OptiDC platform from Kelun’s subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech”).
Development Overview
| Item | Detail |
|---|---|
| Sponsor | Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) |
| Developer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
| Platform | Proprietary OptiDC platform |
| Drug Class | Dual-payload Antibody-Drug Conjugate (ADC) |
| Indication | Advanced solid tumors |
| Regulatory Milestone | NMPA clinical trial approval |
| Approval Date | 28 Jul 2026 |
Drug Profile & Mechanism of Action
- Molecule: SKB565
- Innovation: First-in-class dual-payload design delivering two distinct therapeutic agents simultaneously
- Payload Components:
- Toxin: Cytotoxic agent for direct tumor cell killing
- Immunomodulator: Immune system activator to enhance antitumor response
- Mechanism: Synergistic action through targeted delivery of both payloads directly to tumor tissues, maximizing efficacy while minimizing systemic toxicity
- Platform Advantage: OptiDC platform enables precise payload ratio control and optimized linker stability
Preclinical Evidence
| Parameter | Result |
|---|---|
| Antitumor Activity | Excellent in multiple solid tumor models |
| Safety Profile | Favorable with manageable toxicity |
| Therapeutic Index | Enhanced compared to single-payload ADCs |
| Target Specificity | High tumor tissue selectivity demonstrated |
Preclinical studies have demonstrated that SKB565’s innovative dual-payload approach achieves superior antitumor activity compared to conventional single-payload ADCs, while maintaining a favorable safety profile suitable for clinical development.
Market Impact & Strategic Implications
- China ADC Landscape: Represents another significant advancement in China’s rapidly growing ADC pipeline, positioning Kelun as a key player in next-generation targeted therapies
- Competitive Differentiation: Dual-payload approach addresses limitations of current ADCs by combining direct cytotoxic effects with immune system activation
- Global Potential: Successful clinical development could position SKB565 for international partnerships and regulatory filings beyond China
- Platform Validation: Clinical success would validate Kelun-Biotech’s OptiDC platform for future dual-payload candidates across multiple indications
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for SKB565. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech